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Abstract
Background: MicroRNAs (miRNAs) are small noncoding RNAs about 22 nt long that negatively regulate gene
expression at the post-transcriptional level. Their key effects on various biological processes, e.g., embryonic
development, cell division, differentiation and apoptosis, are widely recognized. Evidence suggests that aberrant
expression of miRNAs may contribute to many types of human diseases, including cancer. Here we present a
database of differentially expressed miRNAs in human cancers (dbDEMC), to explore aberrantly expressed miRNAs
among different cancers.
Results: We collected the miRNA expression profiles of 14 cancer types, curated from 48 microarray data sets in
peer-reviewed publications. The Significance Analysis of Microarrays method was used to retrieve the miRNAs that
have dramatically different expression levels in cancers when compared to normal tissues. This database provides
statistical results for differentially expressed miRNAs in each data set. A total of 607 differentially expressed miRNAs
(590 mature miRNAs and 17 precursor miRNAs) were obtained in the current version of dbDEMC. Furthermore,
low-throughput data from the same literature were also included in the database for validation. An easy-to-use
web interface was designed for users. Annotations about each miRNA can be queried through miRNA ID or
miRBase accession numbers, or can be browsed by different cancer types.
Conclusions: This database is expected to be a valuable source for identification of cancer-related miRNAs, thereby
helping with the improvement of classification, diagnosis and treatment of human cancers. All the information is
freely available through http://159.226.118.44/dbDEMC/index.html.
Background
Cancer, the leading cause of death worldwide, accounts
for millions of deaths and huge economic burdens each
year. One promising strategy for the diagnosis and treat-
ment of cancer is to detect cancer-related biomarkers,
which may have mutated or altered expression when
comparing cancerous and normal tissues. Recently, a
large amount of publicly available data at the genomic,
transcriptomic and proteomic levels on cancers and cor-
responding exploration methods have greatly facilitated
the identification of cancer-related biomarkers. Many
cancer-related databases have been established to pro-
vide this kind of information, such as COSMIC [1],
ITTACA [2], HPtaa [3] and dbDEPC [4]; however, most
of them mainly focus on the protein-coding genes. In
the recent decade, noncoding RNAs, especially the
microRNAs (miRNAs), have been in the limelight of
biomedical research. There is increasing evidence sug-
gesting that the deregulation of miRNAs is associated
with the development of many types of cancer [5-8],
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the diagnosis and treatment of human cancers.
miRNAs are small noncoding RNAs of about 22
nucleotides long which contribute to the post-transcrip-
tional regulation of gene expression. They can inhibit
the translation or strengthen the degradation of target
transcripts through specific binding to messenger RNAs
[9]. In the past few years, thousands of miRNAs have
been identified in many organisms varying from viruses
to mammals [10,11]. Their regulatory roles involved in
different biological processes, such as cell proliferation,
division, differentiation, apoptosis and embryo develop-
ment, are extensively recognized [12-14]. The correla-
tions between the alternation of miRNAs and the
occurrence of human disease, especially in cancer, have
been widely reported. The first evidence for the involve-
ment of miRNAs in cancer formation was reported in
2002 [15]. Calin et al. found that miR-15 and miR-16
are located in a 30-kb region of chromosome 13q14,
which is deleted in over 50% cases of B-cell chronic
lymphocytic leukemia (B-CLL). The subsequent expres-
sion analysis indicated that both miRNAs were deleted
or down-regulated in more than 68% of the cases. In
another example, He et al. demonstrated that the
enhanced expression of miR-17-92 cluster in B-cell lym-
phomas may accelerate c-Myc-induced tumorigenesis.
This was the first time that the direct evidence for the
involvement of miRNA in cancer was presented, thus
miR-17-92 was referred to as oncomir-1 [16]. Interest-
ingly, another work at the same time demonstrated that
c-Myc could induce the expression of miR-17-92 and
E2F1 growth factor, and that the miR-17-92 could inhi-
bit the overexpression of E2F1; therefore, the miR-17-92
cluster could act as either an oncogene or tumor sup-
pressor, depending on the context and cellular environ-
ment [17]. This miRNA cluster was also found to be
up-regulated in lung cancer, while in contrast, another
miRNA family, the let-7, was down-regulated [18,19]. In
addition, downregulation of miR-122 was observed in
hepatocellular carcinomas, whereas many other miRNAs
were up-regulated [20]. It is speculated that more than
50% of the miRNA genes are located at cancer-related
genome locus [21]. Many of them can act as oncogenes
or tumor suppressor genes. Therefore, the identification
of cancer-related miRNAs is of great importance for the
diagnoses and treatment of human cancers.
High-throughput methods have been used to investi-
gate miRNA expression pattern [22-24]. The expression
profiles of miRNAs were believed to be more informa-
tive and accurate for classifying different cancer types in
some cases [25]. As more and more transcriptomic data
on miRNAs is published, several integrated resources
for investigating and analyzing the expression patterns
of miRNAs in normal tissues have been established,
such as microRNA.org [26] and miRGator [27]. How-
ever, the number of databases concerning cancer-related
miRNAs is still limited. To integrate the expression
information of cancer-related miRNAs and improve the
detection and classification of human cancers, we devel-
oped a publicly available database of differentially
expressed miRNAs in human cancers (dbDEMC). This
database integrated the expression data from 48 miRNA
microarray data sets in peer-reviewed publications to
provide the information of expression level change of
miRNAs. In contrast to other databases, for example,
the miR2Disease, which integrated miRNA-disease rela-
tionship mainly from the literature [28], results of
dbDEMC were primarily retrieved from the analysis of
high-throughput expression data, so that more quantita-
tive information could be provided. Furthermore,
dbDEMC is different from S-MED, which mainly
focuses on the sarcoma-related miRNAs [29], in that
dbDEMC provides miRNA expression for a broader
spectrum of cancer cell lines. The establishment of this
database will provide novel insight for cancer-related
research. It could help with the identification of cancer-
related miRNAs and further analysis of the roles that
the miRNA plays in cancer formation, thereby helping
with the improvement of classification, diagnosis and
treatment of human cancers.
Methods and results
Data source
Differentially expressed miRNAs were curated from
high-throughput data by a semiautomatic method. First,
we searched the Gene Expression Omnibus (GEO) data-
base using miRNA-related keywords, i.e., “miRNA” and
“microRNA” and cancer-related keywords including
“cancer”, “tumor”, “carcinoma” , “lymphoma” etc [30].
The search results were limited to those published
before March 2010. For data quality control, only
experiments with at least three biological replicates per-
formed in both cancerous and normal tissues for single
channel intensity data or at least three duplicates for
two channel ratio data were selected. A total of 48 data
sets from different cancer subtypes or cell lines of 14
cancers were chosen after the initial screen. Then the
Significance Analysis of Microarrays (SAM) method was
used to select miRNAs whose mean expression level is
significantly different between cancer and normal tissues
[31]. This method identified statistically differentially
expressed genes by carrying out gene specific t-test.
A “relative difference” score was computed for each
gene. The D value was defined as the average expression
change from different expression states to the standard
deviation of measurements for that gene. Random per-
mutation of the measurement was performed to esti-
mate the false discovery rate (FDR). The siggenens
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bioc/html/siggenes.html] embedded in R was used to
perform the SAM analysis. The miRNAs with Q value
less than 0.05 were extracted as candidate genes that
have significant different expression levels. In addition,
some low-throughput methods, including the quantita-
tive real-time PCR and northern blot, were used to vali-
date the results of the microarray experiment; therefore,
such information from the same literature was also
incorporated into the database. miRNA identifiers were
unified as miRBase IDs [32]. Each entry of the database
contains the miRNA ID, miRBase accession number,
miRNA sequence and detailed information about the
analysis results. Considering the complexity of expres-
sion status of a specific miRNA from different experi-
ments or from different subtypes or cell lines derived
from the same cancer type, an overall expression heat-
map was generated from the average D value for addres-
sing the significance of the miRNA in multiple cancers.
In addition, hyperlinks to the computationally predicted
targets for each miRNA by miRanda [33], PicTar [34]
and TargetScan [35] were also provided.
This release of dbDEMC contains 607 differentially
expressed miRNAs (590 mature miRNAs and 17 pre-
cursor miRNAs) from 14 types of cancer, including
breast cancer, colon cancer, esophageal carcinoma,
head and neck squamous cell carcinoma, hepatocellu-
lar carcinoma, lung cancer, lymphoma, medulloblas-
toma, prostate cancer, renal carcinoma, uterus
carcinoma, glioblastoma, multiple myeloma and
meningioma. The expression information of the 132
miRNAs retrieved from low-throughput experiments
was also included.
Database architecture
The expression information of miRNAs was imported
into the database powered by MySQL. The web inter-
face was implemented using PHP language, and Apache
was used as the HTTP server.
Web interface
dbDEMC provides different ways to navigate the data-
base. For text search, dbDEMC supports miRNA search-
ing via miRNA IDs or miRBase accession numbers
(Figure 1A). Users can also select a specific cancer type
to browse differentially expressed miRNAs (Figure 1B).
A customized BLAST tool is also available for sequence
similarity search [36]. It is useful to determine whether
the query sequence is overlapped with the existing miR-
NAs in the database (Figure 1C). The results page for
Figure 1 T h ew e bi n t e r f a c eo fd b D E M C .(A) Key word search. miRNAs can be searched via miRNA ID or miRBase accession number.
(B) Browse database, users can browse the miRNAs of specific cancers. (C) BLAST. An easy-to-use interface was created for parameter selection.
(D) A part of search result page, consisting of a summary, an expression heatmap and the expression status.
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ing, such as the miRNA ID, summary, cancer type,
related cancer subtypes or cell lines, and expression sta-
tues (up- or down-regulation) (Figure 1D).
Detailed expression information of a specific miRNA
can be accessed via the hyperlink of miRNA ID (Figure 2).
Besides a summary about miRBase accession number,
miRNA sequence and expression change in different can-
cers is also presented. A heatmap was generated to visua-
lize such changes. Results of Differential expression ratio
(D value), stdev, Q value and R fold from different expres-
sion profiles of the miRNA were displayed so that the
degree of deregulated information can be evaluated. In
addition, the miRNA expression information retrieved
from low-throughput experiments were presented if it was
available.
Conclusion
As a novel class of molecular biomarker, cancer-related
miRNAs is of great importance for clinicians and cancer
immunologists to detect. To achieve this goal, we devel-
oped dbDEMC, a database that allows for an effective
retrieval of microRNA expression information in differ-
ent cancers. In summary, we believe this database will
greatly facilitate the identification of cancer-related miR-
NAs and the discrimination and determination of differ-
ent cancer types, as well as their lineage during
development. The dbDEMC may be accessed through
http://159.226.118.44/dbDEMC/index.html. All the
information is freely available to users. As the number
of miRNAs and their corresponding expression profiles
from different cancers increase, this database will be
continually updated.
Discussion
The dbDEMC includes miRNAs that have the expres-
sion information in different cancers determined by sta-
tistical analysis of microarray data. Until now, a total of
607 miRNAs were identified as deregulated in one or
more cancer types, comprising more than half of the
miRNAs discovered in humans [32]. Figure 3A illus-
t r a t e st h en u m b e ro fd i f f e r e n t i a l l ye x p r e s s e dm i R N A s
for each cancer type. Taking breast cancer as an
example, a total of 371 miRNAs were identified to be
differentially expressed, where 202 miRNAs were up-
regulated and 243 miRNAs were down-regulated. Analy-
sis results from different data sources indicated that the
expression levels of a specific miRNA are often different
and even contradict with each other among many
experiments. The different cancer subtypes, cell lines
and the experiment platforms used may be the explana-
tion for these differences. In this sense, the integration
Figure 2 Detailed page of an example miRNA record. The
whole page consists of five major parts: a summary, an expression
heatmap, statistical details, the D value across signatures, and the
low-throughput data for validation.
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reliable miRNA expression information in cancers.
We also compared the content of dbDEMC with can-
cer related miRNAs in miR2Disease. Keywords including
the “cancer”, “carcinoma”, “lymphoma” and “leukemia”
were used to search cancer related miRNAs in miR2Di-
sease and a total of 303 mature miRNAs were retrieved.
By comparison of the 590 mature miRNAs included in
dbDEMC, 253 (42.9%) shared with the above result,
which suggests that dbDEMC will be an important com-
plement to other existing databases.
As candidate biomarkers for diagnosis, treatment and
prognosis of human cancers, the differentially expressed
miRNAs in dbDEMC can be used to infer miRNA-cancer
relationships. Figure 3B demonstrates the number of the
deregulated miRNAs in multiple cancers. 232 miRNAs
(39.3%) have differential expression in only one cancer,
while 267 miRNAs (45.3%) have differential expression in
no less than three cancers. The most prevalent miRNAs
are miR-143 and miR-214, both of which are associated
with twelve cancers types. miR-143 is down-regulated in
ten cancers and has conflicting results in two cancers,
whereas miR-214 is down-regulated in eight cancers, up-
regulated or has conflicting expression results in two can-
cers. Common miRNAs shared by multiple cancers with
similar deregulation status may suggest they have common
regulatory mechanisms and can be regarded as therapeutic
targets. To provide more accurate and reliable miRNA
expression information in multiple cancers, a meta-profìl-
ing analysis of the expression results in the 48 microarray
data sets was performed following Daniel et al [37]. The
meta-profìling analysis addresses significant intersections
of miRNAs shared by different expression signatures,
which are defined here as the statistical results of microar-
ray experiments. For a set of S differential expression sig-
natures, miRNAs were first sorted by the number of
signatures that they presented. Then the number of
miRNAs associated with each possible number of multiple
signatures were calculated (N0,N 1,N 2...NS). Subsequently,
random permutations were performed in which the
D values were randomly assigned to each miRNA within
each signature, so that an index of the number of the miR-
NAs associated with the number of random signatures (E0,
E1,E 2...ES) was generated. A minimum meta-false discov-
ery rate (mFDRmin) was determined to assess the signifi-
cance of the interaction among signatures:
mFDRmin =M I N I M U M( [ Ei +1 ] / [ Ni]) (for i = 0 ... S)
miRNAs were defined as significantly differently
among multiple signatures if mFDRmin < 0.1. The above
steps were repeated as the number of miRNAs was
iteratively lowered by 50% within each signature accord-
ing to the D value until the mFDRmin threshold was
reached. At the initial significant threshold, a total of
107 miRNAs were deregulated in more than 15 signa-
tures, 74 miRNAs were deregulated in more than 20 sig-
natures and one miRNA was deregulated in 46
signatures, whereas for the random simulation, no
miRNA was found to be deregulated in more than 15
signatures. This indicates the statistically significant
multi-signature expression of the 107 miRNAs
(mFDRmin = 0.034) in multiple cancers. The meta-signa-
ture for the 74 miRNAs was depicted in Figure 4. Many
o ft h e s em i R N A sh a v eb e e np r e v i o u s l yd e m o n s t r a t e dt o
be associated with cancers. For example, miR-15 and
miR-16 were shown to be down-regulated in B-cell leu-
kemia and involved in the development of multi-drug
resistance in gastric cancer [15,38]. miR-143 and miR-
145 are down-regulated in colon cancer and B-cell
malignancies [39,40]. A high expression level of miR-
196a may induce colorectal cancer and Barrett’s esopha-
gus [41,42]. Moreover, many miRNAs were shown to be
associated with the development of breast cancer or its
Figure 3 Data content of dbDEMC. (A) The number of the differentially expressed miRNAs in each cancer type. (B) The number of the
differentially expressed miRNAs in multiple cancers.
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miR-221 and miR-222 [43-45]. The common expression
profiling of miRNAs suggests that there a common reg-
ulatory mechanism for cell division and proliferation
may exits. Alternation of transcriptional features may
contribute to unregulated cell division and neoplastic
transformation of the cancer cell. On the other hand,
these small numbers of miRNAs may represent impor-
tant therapeutic targets against cancer.
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